13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001782539
Total reported value
$131.5M
$131.5M
35 檔
36.8%
The Q4 2024 SEC filing reveals that Nan Fung Group Holdings Ltd held a total portfolio value of $131.5M, covering 35 public equity positions.
During Q4 2024, Nan Fung Group Holdings Ltd's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ILMN | Illumina Inc | Stock-Healthcare | 13.62% | — | — | |
| 2 | HRMY | Harmony Biosciences Holdings | Stock-Other | 10.85% | +0.13% | — | |
| 3 | OCS | Oculis Holding AG | Stock-Other | 6.34% | -4.52% | — | |
| 4 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 5.28% | — | — | |
| 5 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 5.26% | — | — | |
| 6 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 4.43% | — | +18.12% | |
| 7 | ✓ | Merus N V | Stock-Other | 4.32% | — | — | |
| 8 | GERN | Geron CORP | Stock-Other | 4.16% | — | — | |
| 9 | INCY | Incyte CORP | Stock-Healthcare | 3.96% | +0.46% | -9.46% | |
| 10 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 3.84% | +0.15% | — | |
| 11 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.58% | — | — | |
| 12 | REPL | Replimune Group Inc | Stock-Other | 3.33% | — | +11.78% | |
| 13 | TRML | Tourmaline Bio Inc | Stock-Other | 3.25% | — | +27.45% | |
| 14 | ONC | Beone Medicines Ltd-adr | Stock-Other | 3.16% | -0.44% | -13.14% | |
| 15 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.06% | — | +24.55% | |
| 16 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 2.94% | -0.13% | +13.93% | |
| 17 | LAB | Standard Biotools Inc | Stock-Other | 2.82% | — | — | |
| 18 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 2.35% | +0.63% | — | |
| 19 | EXEL | Exelixis Inc | Stock-Healthcare | 1.83% | — | — | |
| 20 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 1.62% | +0.09% | — | |
| 21 | ASND | Ascendis Pharma A/S | Stock-Other | 1.60% | -2.57% | EXIT | |
| 22 | RBRK | Rubrik Inc-a | Stock-Tech | 1.36% | — | — | |
| 23 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.12% | — | — | |
| 24 | KYMR | Kymera Therapeutics Inc | Stock-Other | 1.06% | +0.57% | +183.91% | |
| 25 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.83% | — | +118.28% | |
| 26 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.73% | -0.24% | — | |
| 27 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.72% | +1.20% | +163.74% | |
| 28 | CLYM | Climb Bio Inc | Stock-Other | 0.71% | — | — | |
| 29 | RANI | Rani Therapeutics Holdings-a | Stock-Other | 0.58% | -0.01% | — | |
| 30 | BOLT1EUR | Bolt Biotherapeutics Inc | Stock-Other | 0.53% | — | — | |
| 31 | ✓ | Bolt Projs Hldgs Inc | Stock-Other | 0.33% | — | — | |
| 32 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.23% | +0.29% | — | |
| 33 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 0.10% | — | — | |
| 34 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 0.06% | — | — | |
| 35 | ✓ | Affimed N V | Stock-Other | 0.04% | — | — |
According to official SEC Form 13F filings, Nan Fung Group Holdings Ltd reported a total U.S. public equity portfolio value of $131.5M across 35 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ILMN, HRMY, OCS) accounted for 36.8% of total reported equity market value during Q4 2024.
During Q4 2024, Nan Fung Group Holdings Ltd's top holdings by market value included ILMN (13.6%)、HRMY (10.8%)、OCS (6.3%). The largest single position, ILMN, represented 13.6% of total portfolio value.
In Q4 2024, Nan Fung Group Holdings Ltd made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.